No Data
WuXi XDC Announces Leadership and Committee Roles
Wuxi XDC (02268.HK): Kenneth Walton Hitchner III appointed as an independent non-executive director.
Gelonghui November 21st | Wuxi XDC (02268.HK) announced that Stewart John Hen has resigned as an independent non-executive director and as a member of the board of directors' audit committee, remuneration committee, and global strategy committee (collectively referred to as "such committees"), effective from November 21, 2024, in order to devote more time to his other personal commitments. The board of directors also gladly announced that Kenneth Walton Hitchner III has been appointed as an independent non-executive director, effective from November 21, 2024.
Open Source Securities' investment strategy for the pharmaceutical industry in 2025: the long-term industry trend has not changed, focusing on sector stabilization and recovery.
At the current stage, the pharmaceutical policy tends to be stable, the rapidly growing unmet clinical needs under the background of aging, the continuous improvement of enterprise innovation capabilities, and other long-term industrial trends have not changed; at the same time, with the macroeconomic improvement, it is expected that the growth rate of medical insurance revenue suppressing the pharmaceutical sector will marginally increase.
Hong Kong stocks abnormal fluctuations | CRO concept stocks lead the gains, institutions believe that the future performance recovery is worth looking forward to. The listing of innovative drugs in the United States has demands for reducing research and d
CRO concept stocks lead the gains. As of the press release, wuxi xdc (02268) rose by 11.29% to HK$27.6; wuxi apptec (02359) fell by 4.07% to HK$58.8; wuxi bio (02269) rose by 3.09% to HK$17.34; tigermed (03347) rose by 3.05% to HK$38.9.
[Brokerage Focus] Bocom Intl believes that the prospects of domestic CXOs' overseas business are mixed after Trump's election.
Jingu Financial News | Bocom Intl research reports indicate that the outlook for domestic CXO overseas business after Trump's election is mixed: 1) a Republican-controlled Congress may advocate 'America First' in the pharmaceutical supply chain; 2) the fate of the IRA signed by the Biden administration under the Trump government is uncertain; 3) Trump may give more managerial responsibilities to Robert Kennedy in the medical health field, who opposes vaccines and claims to extensively reform the American medical health system, which could bring certain pressure to downstream customers of CXO; 4) Trump's tariff policy and overall loose fiscal policy stance may lead to subsequent inflation.
WuXi XDC Named Best CDMO Winner at 2024 World ADC Awards
No Data
No Data